ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT06678659

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Sponsor

Recursion Pharmaceuticals Inc.

Enrollment

85 participants

Start Date

Nov 21, 2024

Study Type

INTERVENTIONAL

Conditions

Locally AdvancedUnresectableMetastatic CancersRelapsed/Refractory Lymphomas

Summary

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • years or older
  • Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
  • Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
  • Eastern cooperative oncology group (ECOG) performance status ≤ 1
  • Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)

Exclusion Criteria2

  • Received treatment with another RBM39 degrader
  • Clinically significant gastrointestinal (GI) or GI malabsorption

Interventions

DRUGREC-1245

Oral

Locations(6)

City of Hope

Duarte, California, United States

Cleveland Clinic

Cleveland, Ohio, United States

SCRI Oncology Partners - PPDS

Nashville, Tennessee, United States

START Mountain Region

West Valley City, Utah, United States

McGill University Health Centre (MUHC) - The Montreal

Québec, Canada, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06678659

Related Trials

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT0458575076 locations

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

NCT0703834316 locations

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

NCT056796741 location

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

NCT0610205711 locations

e-Motion : Promoting Emotion Regulation in Chronic Cancer

NCT072360212 locations